BioVantra provides a focused portfolio of integrated diagnostic and reporting services with a strong emphasis on prostate cancer care, alongside bladder cancer detection and surveillance support. Each service is designed to produce clearer, more clinically useful information for the teams diagnosing and treating these patients.
Each service can be used on its own or in combination. Descriptions below summarise the clinical intent; follow a service to view the full detail page.
A prostate-focused diagnostic service that integrates cytologic and molecular information into a more structured and clinically useful report.
A structured interpretation service designed to clarify cancer extent, lesion distribution, and treatment-planning relevance.
A non-invasive diagnostic offering that combines urine cytology and molecular analysis in a single integrated report to support bladder cancer detection and surveillance.
Digital pathology and synoptic reporting support intended to improve diagnostic clarity, consistency, and communication.
The portfolio is organized around how information is actually used in prostate cancer diagnosis and treatment, rather than around test menus.
Cytologic, molecular, and pathology information are brought together into a coherent diagnostic view rather than reported in isolation.
Synoptic formats and consistent terminology make findings easier to read, compare, and act on across visits and teams.
Services are shaped around prostate cancer diagnosis and treatment, alongside bladder cancer detection and surveillance.
Outputs are designed to fit into how urologists and other clinicians involved in diagnosis and treatment already work.
We work with urology practices and clinical teams involved in the diagnosis and treatment of prostate and bladder cancer. Share a little about your setting and a member of our team will follow up.